Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib DDI Study with Midazolam, Rosuvastatin, and Metformin
NCT05076877Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma Concentration of Probe Substrates (Midazolam, Rosuvastatin, and Metformin) Co-administered with Lazertinib vs Alone at Day 13. Started Sep 2021; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05076877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076877.